Quantification of Thalamic Atrophy in MS: From the Multicenter Italian Neuroimaging Network Initiative Data Set to Clinical Application

References

1. 1.↵
   1. Haber SN

   . The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003;26:317–30 doi:10.1016/j.jchemneu.2003.10.003 pmid:14729134

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Henry RG,
   2. Shieh M,
   3. Okuda DT, et al

   . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236–44 doi:10.1136/jnnp.2007.134825 pmid:18469033

   Abstract/FREE Full Text
3. 3.↵
   1. Audoin B,
   2. Ranjeva JP,
   3. Au Duong MV, et al

   . Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging 2004;20:765–71 doi:10.1002/jmri.20178 pmid:15503338

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Audoin B,
   2. Davies GR,
   3. Finisku L, et al

   . Localization of grey matter atrophy in early RRMS: a longitudinal study. J Neurol 2006;253:1495–501 doi:10.1007/s00415-006-0264-2 pmid:17093899

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Sepulcre J,
   2. Sastre-Garriga J,
   3. Cercignani M, et al

   . Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006;63:1175–80 doi:10.1001/archneur.63.8.1175 pmid:16908748

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Mesaros S,
   2. Rocca MA,
   3. Absinta M, et al

   . Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70:1107–12 doi:10.1212/01.wnl.0000291010.54692.85 pmid:18272867

   CrossRefPubMed
7. 7.↵
   1. Mesaros S,
   2. Rocca MA,
   3. Pagani E, et al

   . Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years. AJNR Am J Neuroradiol 2011;32:1016–20 doi:10.3174/ajnr.A2430 pmid:21393412

   Abstract/FREE Full Text
8. 8.↵
   1. Rocca MA,
   2. Mesaros S,
   3. Pagani E, et al

   . Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010;257:463–69 doi:10.1148/radiol.10100326 pmid:20724544

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Azevedo CJ,
   2. Cen SY,
   3. Khadka S, et al

   . Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol 2018;83:223–34 doi:10.1002/ana.25150 pmid:29328531

   CrossRefPubMed
10. 10.↵
    1. Filippi M,
    2. Rocca MA,
    3. Pagani E, et al

    ; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014;85:851–58 doi:10.1136/jnnp-2013-306132 pmid:24029546

    Abstract/FREE Full Text
11. 11.↵
    1. Gaetano L,
    2. Haring DA,
    3. Radue EW, et al

    . Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology 2018;90:e1324–32 doi:10.1212/WNL.0000000000005292 pmid:29540589

    Abstract/FREE Full Text
12. 12.↵
    1. Hanninen K,
    2. Viitala M,
    3. Paavilainen T, et al

    . Thalamic atrophy predicts 5-year disability progression in multiple sclerosis. Front Neurol 2020;11:606 doi:10.3389/fneur.2020.00606 pmid:32760339

    CrossRefPubMed
13. 13.↵
    1. Schoonheim MM,
    2. Ciccarelli O

    . The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis. Neurology 2018;90:677–78 doi:10.1212/WNL.0000000000005279 pmid:29540583

    Abstract/FREE Full Text
14. 14.↵
    1. Meijerman A,
    2. Amiri H,
    3. Steenwijk MD, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Reproducibility of deep gray matter atrophy rate measurement in a large multicenter dataset. AJNR Am J Neuroradiol 2018;39:46–53 doi:10.3174/ajnr.A5459 pmid:29191870

    Abstract/FREE Full Text
15. 15.↵
    1. Velasco-Annis C,
    2. Akhondi-Asl A,
    3. Stamm A, et al

    . Reproducibility of brain MRI segmentation algorithms: empirical comparison of local MAP PSTAPLE, FreeSurfer, and FSL-FIRST. J Neuroimaging 2018;28:162–72 doi:10.1111/jon.12483 pmid:29134725

    CrossRefPubMed
16. 16.↵
    1. Bisecco A,
    2. Rocca MA,
    3. Pagani E, et al

    ; MAGNIMS Network. Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: a multicenter study. Hum Brain Mapp 2015;36:2809–25 doi:10.1002/hbm.22809 pmid:25873194

    CrossRefPubMed
17. 17.↵
    FSL MIST. https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/MIST. Accessed May 10, 2023
18. 18.↵
    1. Visser E,
    2. Keuken MC,
    3. Forstmann BU, et al

    . Automated segmentation of the substantia nigra, subthalamic nucleus and red nucleus in 7T data at young and old age. Neuroimage 2016;139:324–36 doi:10.1016/j.neuroimage.2016.06.039 pmid:27349329

    CrossRefPubMed
19. 19.↵
    1. Filippi M,
    2. Tedeschi G,
    3. Pantano P, et al

    ; INNI Network. The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. Neurol Sci 2017;38:1029–38 doi:10.1007/s10072-017-2903-z pmid:28293740

    CrossRefPubMed
20. 20.↵
    1. Lublin FD,
    2. Reingold SC

    . Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11 doi:10.1212/wnl.46.4.907 pmid:8780061

    Abstract/FREE Full Text
21. 21.↵
    1. Storelli L,
    2. Rocca MA,
    3. Pantano P, et al

    ; INNI Network. MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. J Neurol 2019;266:2848–58 doi:10.1007/s00415-019-09509-4 pmid:31422457

    CrossRefPubMed
22. 22.↵
    1. Andersson JL,
    2. Graham MS,
    3. Drobnjak I, et al

    . Towards a comprehensive framework for movement and distortion correction of diffusion MR images: within volume movement. Neuroimage 2017;152:450–66 doi:10.1016/j.neuroimage.2017.02.085 pmid:28284799

    CrossRefPubMed
23. 23.↵
    1. Andersson JL,
    2. Sotiropoulos SN

    . An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage 2016;125:1063–78 doi:10.1016/j.neuroimage.2015.10.019 pmid:26481672

    CrossRefPubMed
24. 24.↵
    1. Behrens TE,
    2. Woolrich MW,
    3. Jenkinson M, et al

    . Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med 2003;50:1077–88 doi:10.1002/mrm.10609 pmid:14587019

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Patenaude B,
    2. Smith SM,
    3. Kennedy DN, et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22 doi:10.1016/j.neuroimage.2011.02.046 pmid:21352927

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Visser E,
    2. Keuken MC,
    3. Douaud G, et al

    . Automatic segmentation of the striatum and globus pallidus using MIST: multimodal image segmentation tool. Neuroimage 2016;125:479–97 doi:10.1016/j.neuroimage.2015.10.013 pmid:26477650

    CrossRefPubMed
27. 27.↵
    1. Fischl B,
    2. Salat DH,
    3. Busa E, et al

    . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–55 doi:10.1016/s0896-6273(02)00569-x pmid:11832223

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Fischl B,
    2. Salat DH,
    3. van der Kouwe AJ, et al

    . Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004;23(Suppl 1):S69–84 doi:10.1016/j.neuroimage.2004.07.016 pmid:15501102

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Battaglini M,
    2. Jenkinson M,
    3. De Stefano N

    . Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp 2012;33:2062–71 doi:10.1002/hbm.21344 pmid:21882300

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Cootes TF,
    2. Taylor CJ,
    3. Cooper DH, et al

    . Active shape models: their training and application. Comput Vis Image Underst 1995;61:38–59 doi:10.1006/cviu.1995.1004

    CrossRefWeb of Science
31. 31.↵
    1. Jacob C

    . Statistical Power Analysis for the Behavioral Sciences. Routledge; 1988:579
32. 32.↵
    1. Rio J,
    2. Nos C,
    3. Tintore M, et al

    . Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344–52 doi:10.1002/ana.20740 pmid:16437558

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Choi EY,
    2. Tian L,
    3. Su JH, et al

    . Thalamic nuclei atrophy at high and heterogenous rates during cognitively unimpaired human aging. Neuroimage 2022;262:119584 doi:10.1016/j.neuroimage.2022.119584 pmid:36007822

    CrossRefPubMed